Job Description Summary
#LI-Hybride
Job Description
Key responsibilities:
Essential Requirements:
Desirable Requirements:
At Novartis Canada, we are determined to be a valued partner and advocate, with a deep understanding of patient needs along the entire care journey – from drug development, to diagnosis, to access and beyond. Part of the way we are doing this is by leveraging data, technology, and partnerships.
Research & Development: we focus on four core therapeutic areas: Cardiovascular, Renal & Metabolic, Immunology, Neuroscience and Oncology. We also develop and deliver treatments through other promoted and established brands, which today are helping millions of patients. Over the last three years, our average annual research and development investment in Canada was over $30 million, and we conduct clinical trial research in every region throughout Canada.
Commitment to Diversity and Inclusion: Novartis is committed to building outstanding, inclusive work environment and diverse team’s representatives of the patients and communities we serve.
Skills Desired
Cross-Functional Collaboration, Data Analysis, Drug Development, Employee Development, Health Sciences, Influencing Skills, Innovation, Inspirational Leadership, Medical Affairs, Patient Care, People Management, Pharmaceutics, Product Launches, Real World Evidence (RWE), Regulatory Compliance, Research Methodologies, Results-Oriented, Stakeholder Engagement, Statistical AnalysisDiscover exciting opportunities in sports technology. Join innovative companies transforming the sports industry through data, media, and cutting-edge tech.
Salary: $180000-260000
🤖 This salary estimate is calculated by AI based on the job title, location, company, and market data. Use this as a guide for salary expectations or negotiations. The actual salary may vary based on your experience, qualifications, and company policies.
Interested in building your career at Novartis? Get future opportunities sent straight to your email.
Create AlertDiscover similar positions that might interest you
Novartis
Novartis
Novartis
Novartis
Novartis
Novartis